1Kravitz, RL, Naihua, D. Design and Implementation of N-of-1 Trials: A User's Guide. Agency for Healthcare Research and Quality, 2014.
2Jackson, SE, Chester, JD. Personalised cancer medicine. Int J Cancer 2015; 137: 262–6.
3Pierson, TM, Yuan, H, Marsh, ED, Fuentes-Fajardo, K, Adams, DR, Markello, T, et al. GRIN2A mutation and early-onset epileptic encephalopathy: personalized therapy with memantine. Ann Clin Transl Neurol 2014; 1: 190–8.
4Davies, SC. Annual Report of the Chief Medical Officer, Genomics. Department of Health and Social Care, 2017.
5McRae, JF, Clayton, S, Fitzgerald, TW, et al. Prevalence and architecture of de novo mutations in developmental disorders. Nature 2017; 542: 433–8.
6Iossifov, I, Roak, BJO, Sanders, SJ, et al. The contribution of de novo coding mutations to autism spectrum disorder. Nature 2014; 515: 216–21.
7Singh, T, Walters, JTR, Johnstone, M, et al. The contribution of rare variants to risk of schizophrenia in individuals with and without intellectual disability. Nat Genet 2017; 49: 1–10.
8Ellul, P, Groc, L, Tamouza, R, Leboyer, M. The clinical challenge of autoimmune psychosis: learning from anti-NMDA receptor autoantibodies. Front Psychiatry 2017; 8: 1–6.
9Clayman, ML, Bylund, CL, Chewning, B, Makoul, G. The impact of patient participation in health decisions within medical encounters. Med Decis Mak 2016; 36: 427–52.
10Nikles, CJ, Clavarino, AM, Del Mar, CB. Using n-of-1 trials as a clinical tool to improve prescribing. Br J Gen Pract 2005; 55: 175–80.
11Shun-shin, MJ, Francis, DP. Is this muscle pain caused by my statin? Br Med J 2017; 3030: 357.
12Donker, T, Petrie, K, Proudfoot, J, Clarke, J, Birch, MR, Christensen, H. Smartphones for smarter delivery of mental health programs: a systematic review. J Med Internet Res 2013; 15: 1–13.
13Palmier-Claus, JE, Ainsworth, J, Machin, M, et al. The feasibility and validity of ambulatory self-report of psychotic symptoms using a smartphone software application. BMC Psychiatry 2012; 12: 172.
14Guyatt, G, Sackett, D, Adachi, J, et al. A clinician's guide for conducting randomized trials in individual patients. CMAJ 1988; 139: 497–503.
15Guyatt, GH, Heyting, A, Jaeschke, R, Keller, J, Adachi, JD, Roberts, RS. N of 1 randomized trials for investigating new drugs. Control Clin Trials 1990; 11: 88–100.
16Guyatt, G, Sackett, D, Taylor, D, Chong, J, Roberts, R, Pugsley, S. Determining optimal therapy – randomized trials in individual patients. N Engl J Med 1986; 314: 889–92.
17Vohra, S, Shamseer, L, Sampson, M, et al. CONSORT extension for reporting N-of-1 trials (CENT) 2015: explanation and elaboration. BMJ 2015; 350: h1793.
18Cochrane Collaboration. Chapter 8: Assessing risk of bias in included studies. In The Cochrane Collaboration, Cochrane Handbook for Systematic Reviews of Interventions 5.1.0 (eds Higgins, JPT, Altman, DG, Sterne, JAC). Cochrane collaboration, 2011.
19Alford, BA. Behavioral treatment of schizophrenic delusions: a single-case experimental analysis. Behav Ther 1986; 17: 637–44.
20MacEwan, GW, Ehmann, TS, Khanbhai, I, Wrixon, C. Donepezil in schizophrenia - Is it helpful? An experimental design case study. Acta Psychiatr Scand 2001; 104: 469–71.
21Kay, S, Opler, L. L-dopa in the treatment of negative schizophrenic syndromes: a single-subject experimental study. Int J Psychiatry Med 1985; 15: 293–8.
22Gorczynski, P, Faulkner, G, Cohn, T, Remington, G. Examining the efficacy and feasibility of exercise counseling in individuals with schizophrenia: a single-case experimental study. Ment Health Phys Act 2014; 7: 191–7.
23Done, DJ, Frith, CD, Owens, DC. Reducing persistent auditory hallucinations by wearing an ear-plug. Br J Clin Psychol 1986; 25: 151–2.
24Blanco-Lopez, MJ, Cudeiro-Blanco, J, Iglesias, G, Gago, A, Cudeiro, J. A simple, repeated rTMS protocol effectively removes auditory verbal hallucinations in a single patient study. Schizophr Res 2016; 172: 224–5.
25Higgins, JPT, Altman, DG, Gøtzsche, PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011; 343: d5928.
26Punja, S, Bukutu, C, Shamseer, L, et al. N-of-1 trials are a tapestry of heterogeneity. J Clin Epidemiol 2016; 76: 47–56.
27Gabler, NB, Duan, N, Vohra, S, Kravitz, RL. N-of-1 trials in the medical literature: a systematic review. Med Care 2011; 49: 761–8.
28Boutron, I, Tubach, F, Giraudeau, B, Ravaud, P. Blinding was judged more difficult to achieve and maintain in nonpharmacologic than pharmacologic trials. J Clin Epidemiol 2004; 57: 543–50.
29McCambridge, J, Witton, J, Elbourne, DR. Systematic review of the Hawthorne effect: new concepts are needed to study research participation effects. J Clin Epidemiol 2014; 67: 267–77.
30Shamseer, L, Sampson, M, Bukutu, C, et al. CONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement. J Clin Epidemiol 2016; 76: 9–17.
31Zucker, DR, Schmid, CH, McIntosh, MW, D'Agostino, RB, Selker, HP, Lau, J. Combining single patient (N-of-1) trials to estimate population treatment effects and to evaluate individual patient responses to treatment. J Clin Epidemiol 1997; 50: 401–10.
32Duan, N, Kravitz, RL, Schmid, CH. Single-patient (n-of-1) trials: a pragmatic clinical decision methodology for patient-centered comparative effectiveness research. J Clin Epidemiol 2013; 66: S21–8.
33Shortreed, SM, Laber, L, Stroup, TS, Pineau, P, Murphy, A. A multiple imputation strategy for sequential multiple assignment randomized trials. Stat Med 2014; 33: 4202–14.
34Stroup, TS, Mcevoy, JP, Swartz, MS, et al. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull 2003; 29: 15–31.
35Riley, RD, Lambert, PC, Abo-Zaid, G. Meta-analysis of individual participant data: rationale, conduct, and reporting. BMJ 2010; 340: c221.